UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934.
Date of Report: May 21, 2018
(Date of earliest event reported)
BioVie Inc.
(Exact name of registrant as specified in its charter)
| Nevada | 333-190635 | 46-2510769 | ||
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) | ||
| 100 Cummings Center, Suite 247-C, Beverly, MA | 01915 | |||
| (Address of principal executive offices) | (Zip Code) | |||
(312) 283-5793
(Registrant’s telephone number, including area code)
NanoAntibiotics, Inc.
(Former Name or Former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.03 Creation of a Direct Financial Obligation.
On May 21, 2018, BioVie Inc. ("BioVie" or “Company”) entered into a demand promissory note in the principal amount of $250,000 (“Note”) in favor of a private investment fund that is unrelated to the Company or any of its officers or directors, and received funds in the same amount. Under certain circumstances, the unpaid balance of the Note may be converted into warrants for common stock of the Company.
| -1- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: May 25, 2018 | BIOVIE INC. | ||||||||
| By: |
/s/ Jonathan Adams |
||||||||
| Jonathan Adams | |||||||||
| Chief Executive Officer | |||||||||
| -2- |